Cooperation in Inspections Activities

Japan, October 2015.

ANVISA

- ANVISA was stablished by Federal Law 9.782/99.
- ANVISA's headquarter is located in Brasília, Brazilian capital.
- Currently ANVISA has approximately 2.000 employees working through the country, most of them is located in Brasília.

ANVISA INSPECTORATE TEAM



Number of employees

GGINP	8
Specialists	**4**
Assistants	**3**
Others	**1**

COIME	28
Specialists	**21**
Assistants	**3**
Others	**4**

CPROD	24
Specialists	**19**
Assistants	**3**
Others	**2**

COISC	13
Specialists	**11**
Assistants	**1**
Others	**1**

Specialists: 55

- There are around 40 inspectors from other Superintendences

GMP CERTIFICATE

Situations in which the GMP certificate is necessary:

- ✓ marketing authorization and
- ✓ post-marketing changing requests.

GMP CERTIFICATE

- Prior to grant initial GMP certificate, it is required a GMP inspection in place.
- Published in the Government Official Journal. Available in www.in.gov.br
- Valid for 2 years after its publication*.
- Can be canceled in case of:
  - confirmed marketing deviations or
  - other significant events.

* The period of 4 years is a new possibility, but still needs to be regulated by Anvisa. (Law 13.043/2014).

GMP INSPECTION

- **Inspection team**: At least two inspectors

- **Inspection duration**:
  - Medicines and API: normally 5 days
  - Medical Devices: normally 4 days

- **Scope:** all GMP elements, per production lines
  - Medicines: Sterile; Non sterile solids; non sterile liquids; etc.
  - Medical Devices: Equipments and Materials; IVDs
  - Active pharmaceutical ingredients: chemical synthesis, derived from animal/ plant sources, herbal extracts

INSPECTION REPORT

- Mention company's general information, inspected areas, non compliance items, legal basis and risk analysis

- For international sites, the final report is issued in **portuguese** and handed over to the company that requested the inspection in Brazil.

COMPANY CLASSIFICATION

- **Satisfactory-** GMP Certificate will be recommended.
- **On demand-** Has maximum **120 calendar days** from requester awareness to comply with all pending requirements described in the report (Resolution RDC nº. 39/2013).
- **Unsatisfactory-** GMP Certificate will not be recommended and Certification process will be rejected.

GMP CERTIFICATE RENEWAL

In case of Certification Renewal, ANVISA will decide if another inspection will be needed based on a risk assessment, considering at least the following aspects:

- *GMP compliance history*
- *Time elapsed since the last inspection*
- *New products/lines inclusion*
- *Marketing complaints*
- *Periodic product review information (except medical devices)*

GMP CERTIFICATE REQUESTS - MEDICINES

Year	Number of Requests	Requests that required inspections
2013	840	241
2014	979	201
2015 (Jan-July)	426	72

INSPECTIONS OVERSEAS - MEDICINES

Number of Inspections by continents:

Year	Europe	Asia	Americas	Africa	Oceania	TOTAL
2013	76	33	23	2	0	134
2014	46	29	22	1	2	100
2015	46	18	19	0	0	83

Inspections in Japan:

Year	Firm	Requester	Production Line
2013	Takeda Pharmaceutical Company Limited	Abbott Laboratórios do Brasil Ltda.	INJECTABLES
2013	Hisamitsu Pharmaceutical Co., Inc.	Hisamitsu Farmacêutica do Brasil Ltda.	SOLIDS, SEMISOLIDS
2014	-	-	-
2015	Tohoku Nipro Pharmaceutical Corporation	AstraZeneca do Brasil Ltda.	SOLIDS
2015	Bushu Pharmaceuticals Ltd.	Daiichi Sankyo Brasil Farmacêutica Ltda.	SOLIDS

Data from January 2013 to July 2015.

GMP CERTIFICATE REQUESTS - API

Year	Number of Requests	Requests that required inspections
2013	96	68
2014	190	157
2015 (Jan-Jul)	97	85

INSPECTIONS OVERSEAS - API

Number of Inspections by continents:

Year	Europe	Asia	Americas	Africa	Oceania	TOTAL
2013	0	19	2	0	0	21
2014	15	14	4	0	1	34
2015	6	19	2	0	0	27

Inspections in Japan:

No inspection was carried out in the 2013-2015 period.

Data from January 2013 to July 2015.

GMP CERTIFICATE REQUESTS – MEDICAL DEVICES

Year	Request*	Requests - Japan
2010	740	45
2011	728	31
2012	673	18
2013	661	28
2014	664	23
2015 (Jan-July)	360	10

* 925 are still waiting inspection to be concluded (http://www.anvisa.gov.br/listadepeticoes/index.asp)

Data from January 2010 to July 2015.

INSPECTIONS OVERSEAS – MEDICAL DEVICES

Number of Inspections by continents:

Year	Europe	Asia	Americas	Africa	Oceania	TOTAL
2013	85	37	82	0	0	204
2014	73	29	48	2	1	153
2015	36	19	58	0	0	113

Inspections in Japan:

Year	Firm
2013	HITACHI ALOKA MEDICAL, LTD
2013	NIDEK CO., LTD
2013	DENKA SEIKEN CO., LTD KAGAMIDA FACTORY
2013	KONICA MINOLTA TECHNOPRODUCTS CO., LTDA
2014	TAKIRON CO., LTD
2014	MIYUKI ELEX CO. LTD
2015	STRYKER MEDTECH K.K.
2015	TERUMO CLINICAL SUPPLY CO. LTD.

Data from January 2013 to July 2015.

International Cooperation

35 bilateral agreements with different countries

Mercosur countries	WHO (vaccines)
Reference NRA (Argentina , Colombia , Cuba and Mexico)	European Directorate for the Quality of Medicines (EDQM)
Australia	France
USA	Germany
Canada	Japan
Denmark	Ireland
Sweden	Italy
UK	Ukraine
Portugal	China
Israel	South Korea
Cape Verde	

International Cooperation

MEDICINES and API

- ✓ EDQM (European Directorate for the Quality of Medicines & HealthCare)
- ✓ CUBA
- ✓ FDA (information exchanges)
- ✓ **JAPAN**
- ✓ Mercosur
  - Argentina
  - Uruguay
- ✓ PIC/S: application phase

Cooperation

- Training programs
- Exchange of inspections information
- Inspectors interchanges (ex.: joint inspections; program for risk-based inspection planning)
- Infrastructure (software, applications, etc.)

International Cooperation

MEDICAL DEVICES

- RDC 39/2013 - GMP certification may occur upon presentation of valid audit report issued by the third party organization auditor, as specific programs, both recognized by ANVISA.

- Law 13.097/2015 - Anvisa can use confidential information about inspections received under agreements with health authorities in other countries, as well as authorize audits at manufacturing plants by national or international institutions accredited by the Agency for such activities.

- RE 2347/2015 - Recognizes the Medical Device Single Audit Program – MDSAP.

International Cooperation

Medical Device Single Audit Program - MDSAP

Goal: reduce analysis times and deadlines of Medical Devices GMP Certification requests.

Proposal: allow MDSAP recognized Auditing Organizations to conduct a single audit of a medical device manufacturer that will satisfy the relevant requirements of the medical device regulatory authorities participating in the pilot program.

International partners that are participating in the MDSAP Pilot include:

- ✓ TGA - Australia
- ✓ ANVISA - Brazil
- ✓ Health Canada
- ✓ MHLW and PAMDA - Japan
- ✓ EU and WHO Prequalification of IVDs Programme - Official Observers.

http://www.fda.gov/MedicalDevices/InternationalPrograms/MDSAPPilot/

Thank you!

Bruno Gonçalves Araújo Rios
suinp@anvisa.gov.br

+55 61 3462-4125

ANVISA
Brazilian Health Surveillance Agency